Concr
Concr is a mission-driven techbio company that leverages advanced computational methods from astrophysics to enable precision oncology. Their platform FarrSight® models complex research and real-world data to predict patient responses to cancer therapies, aiming to improve clinical trial success rates and patient outcomes. Concr's solutions are trusted by industry, academia, and healthcare, and they are supported by a global network of investors and partners. The company's mission is to solve data challenges in cancer care, making personalized treatment accessible to all.
Industries
Nr. of Employees
small (1-50)
Products
Cloud-native predictive modelling platform
A cloud-based analytics platform that integrates clinical, genomic and imaging data to build patient and cohort models, simulate clinical trials, generate synthetic controls, and run bioinformatics analyses.
Cloud-native predictive modelling platform
A cloud-based analytics platform that integrates clinical, genomic and imaging data to build patient and cohort models, simulate clinical trials, generate synthetic controls, and run bioinformatics analyses.
Services
Provision of computational predictive models and simulation services to forecast therapeutic responses for individual patients and cohorts to support drug-development decisions and trial design.
Statistical learning and ML-driven biomarker identification workflows that operate with limited preclinical and clinical data, plus support for clinical validation studies.
Development and validation of deep learning models for cell-type identification and quantitative analysis of H&E whole-slide images to generate image-derived biomarkers.
Operational support for retrospective and prospective clinical observational studies to collect and curate clinical, genomic and imaging data for biomarker validation (example: TNBC VISION study).
Collaborative programs to incorporate external regional or population-specific genomic and clinical datasets to reduce demographic bias in model training and inference.
Provision of computational predictive models and simulation services to forecast therapeutic responses for individual patients and cohorts to support drug-development decisions and trial design.
Statistical learning and ML-driven biomarker identification workflows that operate with limited preclinical and clinical data, plus support for clinical validation studies.
Development and validation of deep learning models for cell-type identification and quantitative analysis of H&E whole-slide images to generate image-derived biomarkers.
Operational support for retrospective and prospective clinical observational studies to collect and curate clinical, genomic and imaging data for biomarker validation (example: TNBC VISION study).
Collaborative programs to incorporate external regional or population-specific genomic and clinical datasets to reduce demographic bias in model training and inference.
Expertise Areas
- Biomarker discovery and validation
- Predictive modelling for oncology
- Clinical trial simulation and synthetic controls
- Digital pathology and histopathology image analysis
Key Technologies
- Bayesian statistical modelling
- Digital twin modelling
- Machine learning / deep learning
- Whole-slide image analysis
News & Updates
Concr will present on transforming cancer care through predictive analytics, highlighting FarrSight®-Twin technology.
Concr received a grant to advance AI-driven biomarkers for triple-negative breast cancer.
Expanding use of genetic data from the Caribbean to improve AI models for cancer treatment.
Recognition for Concr’s innovative approach in early-stage cancer tech.
Featured for delivering impactful cancer solutions and leveraging Cambridge’s innovation ecosystem.
Launching the VISION trial to predict treatment response in early triple-negative breast cancer.
Concr will present on transforming cancer care through predictive analytics, highlighting FarrSight®-Twin technology.
Concr received a grant to advance AI-driven biomarkers for triple-negative breast cancer.
Expanding use of genetic data from the Caribbean to improve AI models for cancer treatment.
Recognition for Concr’s innovative approach in early-stage cancer tech.
Featured for delivering impactful cancer solutions and leveraging Cambridge’s innovation ecosystem.
Launching the VISION trial to predict treatment response in early triple-negative breast cancer.